A role for cytochrome b5 in the in vivo disposition of anti-cancer and cytochrome P450 probe drugs in mice

The role of microsomal cytochrome b 5 (Cyb5) in defining the rate of drug metabolism and disposition has been intensely debated for several decades. Recently we described mouse models involving the hepatic or global deletion of Cyb5, demonstrating its central role in in vivo drug disposition. We hav...

Full description

Saved in:
Bibliographic Details
Published inDrug metabolism and disposition Vol. 42; no. 1; pp. 70 - 77
Main Authors Henderson, Colin J., McLaughlin, Lesley A., Finn, Robert D., Ronseaux, Sebastien, Kapelyukh, Yury, Wolf, C. Roland
Format Journal Article
LanguageEnglish
Published 10.10.2013
Online AccessGet full text

Cover

Loading…
More Information
Summary:The role of microsomal cytochrome b 5 (Cyb5) in defining the rate of drug metabolism and disposition has been intensely debated for several decades. Recently we described mouse models involving the hepatic or global deletion of Cyb5, demonstrating its central role in in vivo drug disposition. We have now used the cytochrome b 5 c omplete n ull (BCN) model to determine the role of Cyb5 in the metabolism of ten pharmaceuticals metabolised by a range of cytochrome P450s, including five anti-cancer drugs, in vivo and in vitro . The extent to which metabolism was significantly affected by the absence of Cyb5 was substrate-dependent, with AUC increased (75-245%), and clearance decreased (35-72%), for phenacetin, metoprolol and chlorzoxazone. Tolbutamide disposition was not significantly altered by Cyb5 deletion, while for midazolam clearance was decreased by 66%. The absence of Cyb5 had no effect on gefitinib and paclitaxel disposition, while significant changes in the in vivo pharmacokinetics of cyclophosphamide were measured (C max and terminal half-life increased 55% and 40%, respectively), tamoxifen (AUC last and C max increased 370% and 233%, respectively) and anastrozole (AUC and terminal half-life increased 125% and 62%, respectively; clearance down 80%). These data from provide strong evidence that both hepatic and extra-hepatic Cyb5 levels are an important determinant of in vivo drug disposition catalysed by a range of cytochrome P450s, including currently-prescribed anti-cancer agents, and that individuality in Cyb5 expression could be a significant determinant in rates of drug disposition in man.
Bibliography:Contributed new reagents or analytic tools: Lesley A. McLaughlin and Sebastien Ronseaux.
Authorship Contributions
Wrote or contributed to the writing of the manuscript: Lesley A. McLaughlin, Robert D. Finn, Colin J. Henderson and C. Roland Wolf
Conducted experiments: Lesley A. McLaughlin, Robert D. Finn and Sebastien Ronseaux
Colin Henderson and Lesley McLaughlin are joint first authors
Participated in research design: Lesley A. McLaughlin, Robert D. Finn, Colin J. Henderson and C. Roland Wolf
Performed data analysis: Lesley A. McLaughlin,Sebastien Ronseaux and Yury Kapeluykh
ISSN:0090-9556
1521-009X
DOI:10.1124/dmd.113.055277